Misetionamide

Chesterbrook, PA, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Persevere Therapeutics, Inc. (“Persevere”), a clinical-stage oncology company developing misetionamide — a first-in-class inhibitor of MYC, historically viewed as undruggable and coined 'the grand orchestrator of cancer growth' — today announced the appointment of James (Jim) Barlow to its Board of Directors. Mr. Barlow is an accomplished biotech CEO and board-level leader with over 25 years of experience in oncology-focused biopharma, spanning business development, clinical development strategy, capital formation, and commercialization. "Jim's appointment comes at an exciting and pivotal moment for Persevere," said Greg Bosch, Chairman and Chief Executive Officer of Persevere Therapeutics. "We are initiating our ‘MIROC-1’ Phase 2a clinical trial in platinum-resistant ovarian cancer this quarter and are a 2026 CPRIT Finalist to fund a Phase 2 trial in pancreatic cancer. Jim has done exactly what we are setting out to do — built a company from the ground up, raised capital creatively, advanced assets into the clinic, and navigated the complex intersection of science, finance, and strategy in oncology. Jim’s experience and network will be invaluable as we advance misetionamide toward patients who desperately need new options." "I am honored to join the Persevere Board at such an exciting juncture," said Mr. Barlow. "Misetionamide represents a potentially transformational therapy for cancer patients, and the company is just launching its Phase 2a trial. I look forward to working with Greg and the team to advance this program and create meaningful value for patients and stakeholders." Mr. Barlow currently serves as President, Chief Executive Officer, and a Board member of ImmunoGenesis, a clinical-stage immuno-oncology company developing next-generation therapies designed to overcome resistance to immune checkpoint blockade. Founded by Michael A. Curran out of MD Anderson Cancer Center in 2019, ImmunoGenesis has been built by Mr. Barlow from its earliest stages. He has led the successful raise of more than $110 million in dilutive and non-dilutive capital, including investments from high-net-worth individuals/family offices, institutional venture financing and two competitive grants from the Cancer Prevention and Research Institute of Texas (CPRIT) and the MD Anderson Cancer Focus Fund. Under his leadership, ImmunoGenesis has secured two IND approvals and advanced multiple assets into the clinic. Prior to ImmunoGenesis, Mr. Barlow served as Vice President of Operations and Business Development at Geneos Therapeutics, where he played a central role in spinning the company out of Inovio Pharmaceuticals, securing Series A financing, negotiating exclusive IP licenses, and advancing the company from financing to IND in under nine months. Earlier in his career, he held senior commercial and strategic roles at Inovio Pharmaceuticals, Bristol Myers Squibb, and Merck & Co., contributing to the launch and lifecycle management of multiple oncology products, including YERVOY ® and OPDIVO ® . Mr. Barlow began his career in investment banking and private equity. He holds an MBA with Honors from the Tepper School of Business at Carnegie Mellon University, where he was a Dean's Scholar, and a B.A. in Mathematical Economics, summa cum laude, from Colgate University. About Persevere Therapeutics Persevere Therapeutics, Inc. is a clinical-stage oncology company developing misetionamide, a first-in-class inhibitor of MYC, historically viewed as undruggable, and coined 'the grand orchestrator of cancer growth'. The company holds two open FDA INDs for ovarian and pancreatic cancers, has completed a 55-patient Phase 1 clinical trial, and is initiating a Phase 2a trial in platinum-resistant ovarian cancer in Q3 2026 at 4 US clinical sites. Persevere is also a 2026 CPRIT Finalist to fund a randomized Phase 2 combination trial in pancreatic cancer. The company was named Persevere as an enduring reminder that we must ‘Never Give Up’ on behalf of cancer patients who persevere every day. Our mission is the singular pursuit of improved clinical outcomes for cancer patients with our novel therapeutic, misetionamide. For more information, visit and follow us on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable securities laws. Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "may," "will," "could," "should," "expects," "intends," "plans," "anticipates," "believes," "estimates," "projects," "potential," or "continue" or similar expressions can be used to identify forward-looking statements. These forward-looking statements include statements regarding the therapeutic potential of misetionamide; plans and expectations for ongoing and future clinical trials. Media and Investor Contact: Ben Steinmentz Persevere Therapeutics, Inc. Ben.Steinmetz@Perseveretherapeutics.com

March 03, 2026 -- Persevere Therapeutics, Inc. (“Persevere”), a Delaware-incorporated, clinical-stage oncology biotechnology company, today announced its official launch following a period of stealth operations. The company is emerging with a Phase 1b/2a-ready clinical asset and the first close of its Seed financing. As part of its launch, Persevere has acquired the clinical-stage program and related assets for misetionamide (GP-2250) from Geistlich Pharma AG. Misetionamide is a novel, first-in-class dual inhibitor of c-MYC and NFκB with clinical activity in a Phase 1 trial. Persevere has closed on a first tranche of a Seed round and is actively engaging prospective investors for the remaining allocation. The company is prepared to share equity round terms with qualified investors. The Seed financing proceeds will be used to complete a Phase 1b/2a proof-of-concept clinical trial evaluating misetionamide in patients with platinum-resistant ovarian cancer (PROC), an area of significant unmet medical need. “We named the company Persevere as an enduring reminder that we must ‘Never Give Up’ on behalf of cancer patients, who persevere every day,” said Greg Bosch, Founder and CEO. “Persevere Therapeutics’ mission is the unwavering pursuit of improved clinical outcomes for cancer patients with our novel therapeutic, misetionamide.” Persevere benefits from the solid foundation already established by the significant effort and investment to-date in the development of misetionamide. These advancements include a broad preclinical program and the completion of a successful Phase 1 clinical trial where 56 cancer patients were treated. Persevere’s investors have a unique opportunity to leverage this prior investment as the company now advances the program into its next stage of clinical development. In addition to the multi-center Phase 1 which demonstrated excellent safety and encouraging efficacy profile of misetionamide, significant milestones have already been achieved including all CMC, toxicology and regulatory hurdles with two open INDs as well as 16 scientific publications and an extensive patent estate. “Platinum resistant ovarian cancer remains one of the most challenging and underserved areas in gynecologic oncology, leaving patients with limited effective options and a poor prognosis,” noted Dr. Robert Coleman, MD, gynecologic oncologist with Texas Oncology and Chief Medical Officer at Vaniam Group. “Persevere’s misetionamide offers a much-needed therapeutic innovation, not only as a differentiated alternative to the growing number of antibody drug conjugates [ADCs] in development, but also as a potential option for patients whose disease has been exposed to, and/or progressed on prior ADC therapy.” Persevere Therapeutics is a clinical-stage oncology company dedicated to advancing a novel antineoplastic therapeutic for patients with difficult-to-treat cancers. The name Persevere reflects an enduring reminder that we must ‘never give up’ on behalf of cancer patients who persevere every day. Our mission is the singular pursuit of improved clinical outcomes for cancer patients with our novel therapeutic, misetionamide (GP-2250). Our lead clinical focus is the treatment of platinum-resistant ovarian cancer. Misetionamide is a broadly active small molecule with a novel mechanism of action that inhibits two oncogenic transcription factors, c-MYC and NFκB. Through modulation of c-MYC, misetionamide selectively disrupts cancer cell energy metabolism, leading to tumor cell death. In parallel, inhibition of NFκB reduces cancer cell proliferation and survival signaling. The company is a privately held Delaware C-corporation headquartered in Chesterbrook, Pennsylvania. The content above comes from the network. if any infringement, please contact us to modify.